White Michael T, Yeung Shunmay, Patouillard Edith, Cibulskis Richard
MRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, Imperial College London, London, United Kingdom.
Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Am J Trop Med Hyg. 2016 Dec 28;95(6 Suppl):52-61. doi: 10.4269/ajtmh.16-0182. Epub 2016 Oct 17.
The continued success of efforts to reduce the global malaria burden will require sustained funding for interventions specifically targeting Plasmodium vivax The optimal use of limited financial resources necessitates cost and cost-effectiveness analyses of strategies for diagnosing and treating P. vivax and vector control tools. Herein, we review the existing published evidence on the costs and cost-effectiveness of interventions for controlling P. vivax, identifying nine studies focused on diagnosis and treatment and seven studies focused on vector control. Although many of the results from the much more extensive P. falciparum literature can be applied to P. vivax, it is not always possible to extrapolate results from P. falciparum-specific cost-effectiveness analyses. Notably, there is a need for additional studies to evaluate the potential cost-effectiveness of radical cure with primaquine for the prevention of P. vivax relapses with glucose-6-phosphate dehydrogenase testing.
要持续减轻全球疟疾负担，就需要为专门针对间日疟原虫的干预措施提供持续资金。要优化利用有限的财政资源，就必须对诊断和治疗间日疟原虫的策略以及病媒控制工具进行成本和成本效益分析。在此，我们回顾了已发表的关于控制间日疟原虫干预措施的成本和成本效益的现有证据，确定了9项侧重于诊断和治疗的研究以及7项侧重于病媒控制的研究。尽管来自更为广泛的恶性疟原虫文献的许多结果可应用于间日疟原虫，但并非总是能够从针对恶性疟原虫的成本效益分析中推断出结果。值得注意的是，需要开展更多研究来评估使用伯氨喹进行根治以预防间日疟原虫复发并结合葡萄糖-6-磷酸脱氢酶检测的潜在成本效益。
